| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5825764 | Clinical Therapeutics | 2012 | 11 Pages |
Abstract
In the Greek NHS and Social Security Sickness Fund setting, panitumumab monotherapy potentially constitutes a cost-saving option (versus cetuximab monotherapy) in the management of patients with mCRC and no mutation of Kirsten rat sarcoma viral oncogene homolog.
Related Topics
Health Sciences
Medicine and Dentistry
Medicine and Dentistry (General)
Authors
Vassilis MSc, Vasilia MSc, Georgia MSc, PhD, Nikolaos MSc, PhD, Georgios MSc, PhD,